61 related articles for article (PubMed ID: 15166029)
1. Pediatric AML primary samples with FLT3/ITD mutations are preferentially killed by FLT3 inhibition.
Brown P; Meshinchi S; Levis M; Alonzo TA; Gerbing R; Lange B; Arceci R; Small D
Blood; 2004 Sep; 104(6):1841-9. PubMed ID: 15166029
[TBL] [Abstract][Full Text] [Related]
2. Improved efficacy of quizartinib in combination therapy with PI3K inhibition in primary FLT3-ITD AML cells.
Darici S; Jørgensen HG; Huang X; Serafin V; Antolini L; Barozzi P; Luppi M; Forghieri F; Marmiroli S; Zavatti M
Adv Biol Regul; 2023 Aug; 89():100974. PubMed ID: 37245251
[TBL] [Abstract][Full Text] [Related]
3. Leukemic mutation FLT3-ITD is retained in dendritic cells and disrupts their homeostasis leading to expanded Th17 frequency.
Flynn PA; Long MD; Kosaka Y; Long N; Mulkey JS; Coy JL; Agarwal A; Lind EF
Front Immunol; 2024; 15():1297338. PubMed ID: 38495876
[TBL] [Abstract][Full Text] [Related]
4. Distinct Metabolic features differentiating FLT3-ITD AML from FLT3-WT childhood Acute Myeloid Leukemia.
Stockard B; Garrett T; Guingab-Cagmat J; Meshinchi S; Lamba J
Sci Rep; 2018 Apr; 8(1):5534. PubMed ID: 29615816
[TBL] [Abstract][Full Text] [Related]
5. Phosphotyrosine-based Phosphoproteomics for Target Identification and Drug Response Prediction in AML Cell Lines.
van Alphen C; Cloos J; Beekhof R; Cucchi DGJ; Piersma SR; Knol JC; Henneman AA; Pham TV; van Meerloo J; Ossenkoppele GJ; Verheul HMW; Janssen JJWM; Jimenez CR
Mol Cell Proteomics; 2020 May; 19(5):884-899. PubMed ID: 32102969
[TBL] [Abstract][Full Text] [Related]
6. Leukemic mutation FLT3-ITD is retained in dendritic cells and disrupts their homeostasis leading to expanded Th17 frequency.
Flynn PA; Long MD; Kosaka Y; Mulkey JS; Coy JL; Agarwal A; Lind EF
bioRxiv; 2023 Sep; ():. PubMed ID: 37781631
[TBL] [Abstract][Full Text] [Related]
7. Profiling
Molina Garay C; Carrillo Sánchez K; Flores Lagunes LL; Jiménez Olivares M; Muñoz Rivas A; Villegas Torres BE; Flores Aguilar H; Núñez Enríquez JC; Jiménez Hernández E; Bekker Méndez VC; Torres Nava JR; Flores Lujano J; Martín Trejo JA; Mata Rocha M; Medina Sansón A; Espinoza Hernández LE; Peñaloza Gonzalez JG; Espinosa Elizondo RM; Flores Villegas LV; Amador Sanchez R; Pérez Saldívar ML; Sepúlveda Robles OA; Rosas Vargas H; Rangel López A; Domínguez López ML; García Latorre EA; Reyes Maldonado E; Galindo Delgado P; Mejía Aranguré JM; Alaez Verson C
Front Pediatr; 2020; 8():586. PubMed ID: 33042924
[No Abstract] [Full Text] [Related]
8. Metabolomic profile of acute myeloid leukaemia parallels of prognosis and response to therapy.
Bolkun L; Pienkowski T; Sieminska J; Godzien J; Pietrowska K; Kłoczko J; Wierzbowska A; Moniuszko M; Ratajczak M; Kretowski A; Ciborowski M
Sci Rep; 2023 Dec; 13(1):21809. PubMed ID: 38071228
[TBL] [Abstract][Full Text] [Related]
9. Targeting Bim via a lncRNA Morrbid Regulates the Survival of Preleukemic and Leukemic Cells.
Cai Z; Aguilera F; Ramdas B; Daulatabad SV; Srivastava R; Kotzin JJ; Carroll M; Wertheim G; Williams A; Janga SC; Zhang C; Henao-Mejia J; Kapur R
Cell Rep; 2020 Jun; 31(12):107816. PubMed ID: 32579941
[TBL] [Abstract][Full Text] [Related]
10. Suberoylanilide hydroxamic acid induces hypersensitivity to radiation therapy in acute myelogenous leukemia cells expressing constitutively active FLT3 mutants.
Chen X; Radany EH; Wong P; Ma S; Wu K; Wang B; Wong JY
PLoS One; 2013; 8(12):e84515. PubMed ID: 24367670
[TBL] [Abstract][Full Text] [Related]
11. Crotonoside exhibits selective post-inhibition effect in AML cells via inhibition of FLT3 and HDAC3/6.
Li YZ; Yu S; Yan PA; Gong DY; Wu FL; He Z; Yuan YY; Zhao AY; Tang X; Zhang RQ; Peng C; Cao ZX
Oncotarget; 2017 Nov; 8(61):103087-103099. PubMed ID: 29262547
[TBL] [Abstract][Full Text] [Related]
12. Gene regulatory network analysis predicts cooperating transcription factor regulons required for FLT3-ITD+ AML growth.
Coleman DJL; Keane P; Luque-Martin R; Chin PS; Blair H; Ames L; Kellaway SG; Griffin J; Holmes E; Potluri S; Assi SA; Bushweller J; Heidenreich O; Cockerill PN; Bonifer C
bioRxiv; 2023 Jul; ():. PubMed ID: 37503022
[TBL] [Abstract][Full Text] [Related]
13. Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3/ITD Acute Myeloid Leukemia: A Report from the Children's Oncology Group.
Tarlock K; Alonzo TA; Gerbing RB; Raimondi SC; Hirsch BA; Sung L; Pollard JA; Aplenc R; Loken MR; Gamis AS; Meshinchi S
Clin Cancer Res; 2016 Apr; 22(8):1951-7. PubMed ID: 26644412
[TBL] [Abstract][Full Text] [Related]
14. SKLB-677, an FLT3 and Wnt/β-catenin signaling inhibitor, displays potent activity in models of FLT3-driven AML.
Ma S; Yang LL; Niu T; Cheng C; Zhong L; Zheng MW; Xiong Y; Li LL; Xiang R; Chen LJ; Zhou Q; Wei YQ; Yang SY
Sci Rep; 2015 Oct; 5():15646. PubMed ID: 26497577
[TBL] [Abstract][Full Text] [Related]
15. The Biology and Targeting of FLT3 in Pediatric Leukemia.
Annesley CE; Brown P
Front Oncol; 2014; 4():263. PubMed ID: 25295230
[TBL] [Abstract][Full Text] [Related]
16. Molecular therapeutic approaches for pediatric acute myeloid leukemia.
Tasian SK; Pollard JA; Aplenc R
Front Oncol; 2014; 4():55. PubMed ID: 24672775
[TBL] [Abstract][Full Text] [Related]
17. Development and validation of a single-cell network profiling assay-based classifier to predict response to induction therapy in paediatric patients with de novo acute myeloid leukaemia: a report from the Children's Oncology Group.
Lacayo NJ; Alonzo TA; Gayko U; Rosen DB; Westfall M; Purvis N; Putta S; Louie B; Hackett J; Cohen AC; Cesano A; Gerbing R; Ravindranath Y; Dahl GV; Gamis A; Meshinchi S
Br J Haematol; 2013 Jul; 162(2):250-62. PubMed ID: 23682827
[TBL] [Abstract][Full Text] [Related]
18. Pediatric relapsed or refractory leukemia: new pharmacotherapeutic developments and future directions.
August KJ; Narendran A; Neville KA
Drugs; 2013 Apr; 73(5):439-61. PubMed ID: 23568274
[TBL] [Abstract][Full Text] [Related]
19. Aberrant Mer receptor tyrosine kinase expression contributes to leukemogenesis in acute myeloid leukemia.
Lee-Sherick AB; Eisenman KM; Sather S; McGranahan A; Armistead PM; McGary CS; Hunsucker SA; Schlegel J; Martinson H; Cannon C; Keating AK; Earp HS; Liang X; DeRyckere D; Graham DK
Oncogene; 2013 Nov; 32(46):5359-68. PubMed ID: 23474756
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
